Last updated on September 2015

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care


Brief description of study

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Detailed Study Description

The primary objective of this study is to:

  • Demonstrate whether, in addition to standard of care (SoC), finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular (CV) mortality and morbidity in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease (DKD)

Clinical Study Identifier: TX141422

Contact Investigators or Research Sites near you

Start Over

Tracy Spinola

Chase Medical Research, LLC
Waterbury, CT USA
  Connect »